James A Whitlock, Jemily Malvar, Luciano Dalla-Pozza, John M Goldberg, Lewis B Silverman, David S Ziegler, Andishe Attarbaschi, Patrick A Brown, Rebecca A Gardner, Paul S Gaynon, Raymond Hutchinson, Van T Huynh, Sima Jeha, Leigh Marcus, Yoav Messinger, Kirk R Schultz, Jeannette Cassar, Franco Locatelli, C Michel Zwaan, Brent L Wood, Richard Sposto, Lia Gore
Children with relapse of T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) have a dismal prognosis, largely due to difficulty attaining second remission. We hypothesized that adding etoposide and cyclophosphamide to the nucleoside analog nelarabine could improve response rates over single-agent nelarabine for relapsed T-ALL and T-LBL. This phase I dose-escalation trial's primary objective was to evaluate the dose and safety of nelarabine given in combination with etoposide at 100 mg/m2 /day and cyclophosphamide at 330-400 mg/m2 /day, each for 5 consecutive days in children with either T-ALL (13 patients) or T-LBL (10 patients)...
August 21, 2022: Pediatric Blood & Cancer